With expansion a prime focus for businesses
worldwide, many are looking
EUROPE & MIDDLE EAST by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
towards rapidly establishing new regions of growth, particularly in Europe and the Middle East.
Nottingham Signs Partnership Agreement with Chinese Pharma Giant
Under the agreement, which was coordinated by the University’s Asia Business Centre, CRPG will partner with Nottingham in a number of ways, including training, staff exchanges, student internships and research and development.
In addition, CRPG has built a pharmaceutical industrial park in Beijing which has been funded by the Chinese government. The company will work with the University to develop this park by learning from the BioCity model, a Nottingham based bioscience incubation centre of which the University is a co-founder.
Speaking at the signing, Professor Chris Rudd, Pro-Vice Chancellor for External Engagement at the University, said: “We are very excited to be expanding our links with CPRG. The company is one of the biggest pharmaceutical manufacturers in China, and this agreement will see many of our staff and students working with CPRG on a range of new projects and initiatives.”
Professor Chris Rudd Pro-Vice Chancellor of the University of Nottingham with Madam Jisheng Chen, General manager of CRPG at the partnership signing.
The University of Nottingham has signed a wide-reaching memorandum of understanding with China Resources Pharmaceutical Group (CRPG) in Beijing, which will see close collaboration between the two organisations in a range of areas.
Last year, Madam Jisheng Chen, the General Manager of CRPG, received an honorary professorship from Nottingham University Business School in recognition of her outstanding achievements in the fi eld of healthcare and pharmaceutical industry.
31430pr@reply-direct.com Acquisition Raises IDS’ Automated Assay Profi le
Immunodiagnostic Systems, a leading solution provider to the clinical laboratory diagnostic market, has augmented its endocrinology pipeline with the acquisition of Italian company Diametra, a developer of manual immunoenzymatic assays. The strategic move follows recent collaboration on the conversion of one of Diametra’s manual assays onto the fully automated IDS-iSYS instrument and IDS plans to add further manual assays in the area of steroid hormones to the instrument’s profi le.
Employing approximately 25 staff Diametra, based in Spello, Umbria, generated revenues of €3.3 million and an EBIT of €0.3 million year-end 31 December 2013. The acquisition also provides IDS with additional development and manufacturing capabilities.
Patrik Dahlen, CEO of IDS, commented: “We are delighted to have secured the acquisition of Diametra, which will assist in the acceleration of our strategic plan outlined earlier this year. In particular, Diametra
will provide immediate access to endocrinology manual assays in the area of steroid hormones that can be converted to automated assays for our iSYS instrument. We continue to pursue complementary acquisitions that will help us grow our specialist endocrinology menu and build operational excellence.”
Focused internally on developing an endocrinology excellence menu and working with partners to develop assay panels in complementary indication fi elds, IDS sells its products primarily in the clinical laboratory market across a range of customers from reference laboratories to physician offi ce laboratories. IDS has fi eld sales forces in certain European countries, including France and Germany, the United States and Brazil and works with distributors in other markets including China, Italy and Spain.
31681pr@reply-direct.com
Business
Opportunities
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144
